These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
534 related articles for article (PubMed ID: 31753525)
1. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525 [TBL] [Abstract][Full Text] [Related]
2. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL; Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357 [TBL] [Abstract][Full Text] [Related]
4. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760 [TBL] [Abstract][Full Text] [Related]
5. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246 [TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786 [TBL] [Abstract][Full Text] [Related]
7. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates. Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222 [TBL] [Abstract][Full Text] [Related]
8. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478 [TBL] [Abstract][Full Text] [Related]
9. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East. Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404 [TBL] [Abstract][Full Text] [Related]
10. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802 [TBL] [Abstract][Full Text] [Related]
11. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Song H; Cicek MS; Dicks E; Harrington P; Ramus SJ; Cunningham JM; Fridley BL; Tyrer JP; Alsop J; Jimenez-Linan M; Gayther SA; Goode EL; Pharoah PD Hum Mol Genet; 2014 Sep; 23(17):4703-9. PubMed ID: 24728189 [TBL] [Abstract][Full Text] [Related]
12. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Stasenko M; Cybulska P; Feit N; Makker V; Konner J; O'Cearbhaill RE; Alektiar KM; Beal K; Gardner GJ; Long Roche KC; Sonoda Y; Chi DS; Zivanovic O; Leitao MM; Cadoo KA; Tew WP Gynecol Oncol; 2019 Jul; 154(1):144-149. PubMed ID: 31113680 [TBL] [Abstract][Full Text] [Related]
13. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA; Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients. Hasmad HN; Lai KN; Wen WX; Park DJ; Nguyen-Dumont T; Kang PCE; Thirthagiri E; Ma'som M; Lim BK; Southey M; Woo YL; Teo SH Gynecol Oncol; 2016 May; 141(2):318-322. PubMed ID: 26541979 [TBL] [Abstract][Full Text] [Related]
15. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829 [TBL] [Abstract][Full Text] [Related]
17. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer. Lavie O; Chetrit A; Novikov I; Sadetzki S; Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026 [TBL] [Abstract][Full Text] [Related]
18. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer. Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422 [TBL] [Abstract][Full Text] [Related]
19. Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review. Kwon BS; Byun JM; Lee HJ; Jeong DH; Lee TH; Shin KH; Suh DS; Kim KH Cancer Res Treat; 2019 Jul; 51(3):941-950. PubMed ID: 30309222 [TBL] [Abstract][Full Text] [Related]
20. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]